These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 10337381)
1. Cytoprotection: shelter from the storm. Klein P; Muggia FM Oncologist; 1999; 4(2):112-21. PubMed ID: 10337381 [No Abstract] [Full Text] [Related]
2. A single center retrospective analysis of a protocol for high-dose methotrexate and leucovorin rescue administration. Cerminara Z; Duffy A; Nishioka J; Trovato J; Gilmore S J Oncol Pharm Pract; 2019 Jan; 25(1):76-84. PubMed ID: 28942720 [TBL] [Abstract][Full Text] [Related]
3. Trimetrexate as a biochemical modulator of 5-fluorouracil and leucovorin in colorectal cancer. Punt CJ Semin Oncol; 2000 Oct; 27(5 Suppl 10):88-90. PubMed ID: 11049038 [No Abstract] [Full Text] [Related]
5. Severe complications after high-dose methotrexate treatment. Takami M; Kuniyoshi Y; Oomukai T; Ishida T; Yamano Y Acta Oncol; 1995; 34(5):611-2. PubMed ID: 7546826 [No Abstract] [Full Text] [Related]
6. Genetic polymorphisms of folate metabolic enzymes and toxicities of high dose methotrexate in children with acute lymphoblastic leukemia. Pakakasama S; Kanchanakamhaeng K; Kajanachumpol S; Udomsubpayakul U; Sirachainan N; Thithapandha A; Hongeng S Ann Hematol; 2007 Aug; 86(8):609-11. PubMed ID: 17323057 [No Abstract] [Full Text] [Related]
7. [Correct use of methotrexate]. Verduijn MM; van den Bemt BJ; Dijkmans BA; van der Waal RI; Horikx A Ned Tijdschr Geneeskd; 2009; 153():A696. PubMed ID: 19785852 [TBL] [Abstract][Full Text] [Related]
8. [Neurotoxicity of antineoplastic antimetabolites and antineoplastic antibiotics]. Morimatsu M Ryoikibetsu Shokogun Shirizu; 1999; (27 Pt 2):571-5. PubMed ID: 10434724 [No Abstract] [Full Text] [Related]
9. Case files of the New York City Poison Control Center: antidotal strategies for the management of methotrexate toxicity. Smith SW; Nelson LS J Med Toxicol; 2008 Jun; 4(2):132-40. PubMed ID: 18570175 [No Abstract] [Full Text] [Related]
10. Design, conduct, and interpretation of organ impairment studies in oncology patients. Takimoto CH; Mita AC J Clin Oncol; 2006 Jul; 24(21):3509-10; author reply 3510-1. PubMed ID: 16849773 [No Abstract] [Full Text] [Related]
11. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant. Meropol NJ; Rustum YM; Creaven PJ; Blumenson LE; Frank C Cancer Invest; 1999; 17(1):1-9. PubMed ID: 10999043 [TBL] [Abstract][Full Text] [Related]
12. Accumulation of plasma reduced folates after folic acid administration. Priest DG; Schmitz JC; Bunni MA Semin Oncol; 1999 Apr; 26(2 Suppl 6):38-41. PubMed ID: 10598553 [TBL] [Abstract][Full Text] [Related]
13. Methotrexate during the first trimester of pregnancy. Prescrire Int; 2010 Oct; 19(109):213. PubMed ID: 21180377 [No Abstract] [Full Text] [Related]
14. Transient encephalopathy following high-dose methotrexate. Lee AC; Li CH; Wong YC Med Pediatr Oncol; 2003 Jul; 41(1):101. PubMed ID: 12764767 [No Abstract] [Full Text] [Related]
15. Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid. Cohen IJ Pediatr Hematol Oncol; 2003 Dec; 20(8):579-81. PubMed ID: 14578026 [TBL] [Abstract][Full Text] [Related]
16. [Managing methotrexate toxicity: a case report]. Fernández Megía MJ; Alós Almiñana M; Terol Castera MJ Farm Hosp; 2004; 28(5):371-4. PubMed ID: 15504095 [TBL] [Abstract][Full Text] [Related]